#### General:

- ld of document version: 12950381
- Status of the document <ep-bulletin>: New publication A1, A2, B1, B2 or B3 published for the first time
- Changed tag from previous publication of document <B002EP><ep-chgt-info>:
- Publication number of the document (EPO or WIPO) <B110>: 2683385
- Kind of document <B130>: B1
- EPO Application number <B210>: 12711500.4
- Application filing date <B220>: 2012.03.09
- Date of refusal of application <B235>:
- Date of withdrawal of application <B235>:
- Date of application deemed withdrawn <B237>:
- Date of receipt of request for re-establishment of rights <B238EP>:
- Date of decision for re-establishment of rights <B238>:
- Date of making available to the public by printing or similar process of an unexamined patent document, on which no grant has taken place on or before the said date <B430>: 2014.01.15
- Date of making available to the public by printing or similar process of a patent document on which grant has taken place on or before the said date <B450><date>: 2018.06.06
- Number of the EPO Bulletin in which the mention of the grant is published. <B450><bnum>: 201823
- Date of rejection of the opposition procedure <B787>:
- Date of termination of the opposition procedure <B788>:
- Due date for translation: 2018.09.06
- Text when the inventor has agreed to waive his entitlement to designation. <B009EP><text[j]>:
- Date of reception of document: 2018.06.08
- Date of publication <B140>: 2018.06.06

#### Priority <B300>:

Number(s) assigned to priority application(s) <b310>:</b310>	Date(s) of filing of priority application(s) <b320>:</b320>	National property office allotting the priority application number or the organization allotting the regional priority application Number (WO for PCT) – country code <b330>:</b330>
	2011.03.10	US

	country code <b330>:</b330>
2011.03.10	US

Lapse <B472>:

No lapse.

#### Classification <B500>:

IPC (8) as one fixed length field of 50 positions <b510ep><text>:</text></b510ep>	Edition of IPC (IPC version) <b516>:</b516>
A61K 31/505 20060101AFI20171220BHEP	8
A61P 17/00 20060101ALI20171220BHEP	8

Title <B540>: No title.

Division <B620> or <B620EP>: No division.

### EPO Customer <B710>&<B720>&<B730>&<B740>:

Inventor

Name <snm>:</snm>	J A Kemp	EPO number of the customer <iid>:</iid>	101669666
Address <street>, <city>, <ctry>:</ctry></city></street>	14 South Square Gray London WC1R 5JJ GB	y's Inn	
Customer type:	Attorney / Agent	Status:	0
Name <snm>:</snm>	MAGILAVY, Daniel	EPO number of the customer <iid>:</iid>	
Address <street>, <city>, <ctry>:</ctry></city></street>	1933 Laguna Street San Francisco, CA 94 US	115	
Customer type:	Inventor	Status:	0
Name <snm>:</snm>	PINE, Polly	EPO number of the customer <iid>:</iid>	
Address <street>, <city>, <ctry>:</ctry></city></street>	786 Partridge Ave. Menlo Park, CA 94029 US	5	

Status:

0

**Customer type:** 

Name <snm>:</snm>	Rigel Pharmaceuticals, Inc.	EPO number of the customer <iid>:</iid>	100208754
Address <street>, <city>, <ctry>:</ctry></city></street>	1180 Veterans Boulevard South San Francisco, CA 94080 US		
Customer type:	Grantees	Status:	0

Opposition <B780>: No opposition.

# **Designated countries <B840>:**

Kind of document <b130>:</b130>	Date of publication <b140>:</b140>	Country code <b840><ctry>:</ctry></b840>
B1	2018.06.06	NO

## PCT <B860>&<B870>:

Kind of document <b130>:</b130>	B1		
PCT Application number <b861><anum>:</anum></b861>	US2012028429	Date of filing <b861><date>:</date></b861>	2012.03.09
PCT Publication number <b871><pnum>:</pnum></b871>	WO2012122452	Publication date <b871><date>:</date></b871>	2012.09.13
Issue number of the Gazette <b871><bnum>:</bnum></b871>	201237	Country code <b862>:</b862>	en

### Citations <B560>:

Kind of document <b130>:</b130>	Type <b561> or <b562>:</b562></b561>	Text <b561><text> or <b562><text>:</text></b562></text></b561>	
---------------------------------	--------------------------------------	--	--

B1	PT citation	US-B2- 7 491 732
B1	Non PT citation	CHANG B Y ET AL: "JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice", JOURNAL OF IMMUNOLOGY 20090801 AMERICAN ASSOCIATION OF IMMUNOLOGISTS USA LNKD-DOI:10.4049/JIMMUNOL.0804063, vol. 183, no. 3, 1 August 2009 (2009-08-01), pages 2183-2192, XP055025639, ISSN: 0022-1767
B1	Non PT citation	Paolo Fabbri ET AL: "Cutaneous lupus erythematosus Scientific editor: Prof Benvenuto Giannotti", , 1 January 2004 (2004-01-01), XP055279452, Retrieved from the Internet: URL:https://www.orpha.net/data/path -Cutaneous-lupus-erythematosus.pdf [retrieved on 2016-06-09]